标签归档：levodopa

L-DOPA sodium (Synonyms: Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
L-DOPA sodium  (Synonyms: Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium)

L-DOPA (Levodopa) sodium 是一种具有口服活性的神经递质多巴胺的代谢前体。L-DOPA sodium 可以透过血脑屏障，并在大脑中转化为多巴胺。L-DOPA sodium 具有抗痛觉过敏作用，可用于帕金森氏病的研究。

L-DOPA sodium (Synonyms: Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium)

L-DOPA sodium Chemical Structure

CAS No. : 63302-01-2

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

L-DOPA sodium 的其他形式现货产品:

L-DOPA

L-DOPA sodium 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性

L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson’s disease research[1][2][3].

IC50 & Target

Human Endogenous Metabolite

 

体内研究
(In Vivo)

L-DOPA sodium (20 mg/kg; orally) reduces Rotenone-induced motor dysfunction[3].
L-DOPA sodium (0-100 mg/kg; orally) reverses tactile, cold and heat allodynia in neuropathic rat without any side effect in sprague-Dawley rats[4].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J mice (7-week-old)[3]
Dosage: 20 mg/kg
Administration: Orally
Result: Reduced Rotenone-induced motor dysfunction.
Animal Model: Sprague-Dawley rats[4]
Dosage: 10, 30, 50, 70, and 100 mg/kg
Administration: Orally
Result: Reverses tactile, cold and heat allodynia in neuropathic rat without any side effect.

Clinical Trial

分子量

219.17

Formula

C9H10NNaO4
CAS 号

63302-01-2
结构分类
  • Alkaloids
  • Other Alkaloids
  • Phenols
  • Polyphenols
初始来源
  • 内源性代谢物
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (547 KB) 产品使用指南 (1538 KB)

参考文献

  • [1]. Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10.  [Content Brief]

    [2]. Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson’s disease. Parkinsonism Relat Disord. 2008;14(4):273-80. Epub 2007 Nov 7.  [Content Brief]

    [3]. Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson’s Disease. Front Aging Neurosci. 2018 Aug 3;10:237.  [Content Brief]

    [4]. Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1;54(2):330-5.  [Content Brief]

    [5]. M Lundblad, et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol. 2005 Jul;194(1):66-75.  [Content Brief]

    [6]. Jie Zhang, et al. Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. Brain Res. 2003 Dec 12;993(1-2):54-8.  [Content Brief]

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务